Nikhil Prasad Fact checked by:Thailand Medical News Team Mar 31, 2026 1 hour, 52 minutes ago
Medical News: Sudden vision loss can strike without warning, often leaving patients frightened and uncertain about their future. One of the most serious causes is central retinal artery occlusion (CRAO), a condition sometimes described as a “stroke of the eye.” A new comprehensive analysis is now shedding light on two of the most widely discussed treatment approaches, offering fresh hope and clearer direction for patients and doctors alike.
New research compares two promising treatments offering hope for sudden vision loss patients
Understanding a Devastating Eye Emergency
CRAO occurs when blood flow to the retina is suddenly blocked, depriving the eye of oxygen. This can lead to rapid and often severe vision loss in one eye. The condition is rare but serious, affecting roughly one in 100,000 people each year, mostly older adults. Without treatment, recovery is poor, with only a small percentage of patients regaining meaningful vision.
Because the retina has one of the highest oxygen demands in the body, even a short interruption can cause lasting damage. This makes timing critical. Experts often stress that “time is eye,” meaning that the sooner treatment begins, the better the chances of preserving sight.
Two Competing Treatment Strategies
The new study compared two main treatments: hyperbaric oxygen therapy (HBOT) and intravenous thrombolysis (IVT). HBOT involves placing patients in a pressurized chamber where they breathe nearly pure oxygen, helping deliver oxygen to the retina even when blood flow is reduced. IVT, on the other hand, uses clot-dissolving drugs to reopen blocked blood vessels.
Researchers from multiple institutions contributed to this analysis, including Northeast Ohio Medical University, Arizona State University, University of Pretoria, University Hospitals Eye Institute at Case Western Reserve University, Cleveland Clinic Foundation, and Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
What the Study Found
The analysis reviewed 25 studies involving 781 patients. Both treatments showed encouraging results. Patients receiving HBOT experienced significant improvement in visual acuity, while those receiving IVT showed similar gains. In practical terms, nearly 46 percent of patients treated with HBOT and about 42 percent treated with IVT achieved meaningful vision improvement.
Interestingly, while both treatments performed similarly overall, they differed in how they work and when they are used. IVT is typically given within a narrow window of about 4.5 hours after symptoms begin, while HBOT may still offer benefits even when started later, depending on availability.
This
Medical News report highlights that both therapies improved vision by measurable margins, but differences in treatment timing and patient selection may influence outcomes.
Safety and Risks to Consider
Each tr
eatment comes with its own risks. HBOT is generally well tolerated but can cause ear pressure injuries, anxiety, or discomfort due to the pressurized chamber. IVT carries more serious potential complications, including bleeding in the brain or other parts of the body, although such events are relatively rare. The study found that overall complication rates were similar between the two treatments, but the types of side effects were very different. This means doctors must carefully consider each patient’s condition before choosing a therapy.
Why Timing and Access Matter
One of the biggest challenges in treating CRAO is access. IVT is often available quickly in hospitals with stroke units, while HBOT requires specialized equipment that may not be widely accessible. As a result, treatment decisions are often influenced not just by medical factors, but also by location and resources.
The research also emphasized that earlier treatment generally leads to better outcomes, especially for IVT. However, HBOT may still provide benefits even when patients arrive later, making it an important option in certain cases.
Conclusion
This study provides important insights into two key treatments for a condition that has long lacked clear solutions. Both hyperbaric oxygen therapy and intravenous thrombolysis can improve vision in patients with CRAO, but neither is a perfect solution. The findings suggest that treatment should be tailored to each patient, taking into account timing, risks, and availability of care. Importantly, the results also highlight the urgent need for larger, well-designed clinical trials to directly compare these therapies and establish clearer guidelines. Until then, doctors must rely on careful judgment and rapid decision-making to give patients the best possible chance of preserving their sight.
The study findings were published in the peer reviewed Journal of Clinical Medicine.
https://www.mdpi.com/2077-0383/15/7/2628
For the latest on central retinal artery occlusions, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/ophthalmology-(eye-diseases)
Share
Tweet
Share
